Objective: The Korean Radiation Oncology Group (12-02) investigated the outcome of stereotactic ablative radiotherapy for hepatocellular carcinoma ≤5 cm using 60 Gy in three fractions. To evaluate dosimetric differences and compliance in a multicenter trial, a planning dummy run procedure was performed. Methods: All six participating institutions were provided the contours of two dummy run cases. Plans were performed following the study protocol to cover the planning target volume with a minimum of 90% of the prescription dose and to satisfy the constraints for organs at risk. We assessed the institutional variations in plans using dose-volume histograms. Results: Different planning techniques were applied: static intensity-modulated radiotherapy in two institutions, CyberKnife in two institutions and RapidArc in two institutions. The conformity index of all 12 plans was ≤1.2. In terms of the planning target volume coverage, all participants followed our study protocol. For the second dummy run case, located in Segment 8 near the heart, the minimum dose of the planning target volume (D 99% : dose covering 99% of the planning target volume) was variable because there was no mention of constraints of D 99% of the planning target volume in the study protocol. As an important organ at risk, the normal liver volumes receiving <17 Gy in all 12 plans were >700 ml. Conclusions: Dosimetric parameters showed acceptable compliance with the study protocol. However, we found the possibility of underdose to the planning target volume if the hepatocellular carcinoma lesion was located near organs at risk such as the heart. Based on this dummy run, we will conduct individual case reviews to minimize the effects of study protocol deviation.
Introduction
Stereotactic ablative radiotherapy (SABR), as an emerging treatment method, which delivers a high dose of radiation to the target, either a single dose or a small number of fractions with a high degree of precision within the body and applies new radiobiology, which was applied to the treatment of hepatocellular carcinoma (HCC) for the first time in 1995 (1) (2) (3) . Since then, several prospective and retrospective studies on SABR for HCC have reported promising treatment results (4) (5) (6) (7) . In Korea, SABR has been actively applied in the treatment of HCC with the increase of the application rate of radiotherapy (RT) to HCC (8, 9) . Recent prospective Phase I and II trials of SABR for HCC conducted at one institution in Korea reported comparable treatment outcomes (10, 11) . In particular, the 2-year local control rate was reported as 94.6% in a Phase II trial wherein 42-60 Gy was delivered in three fractions (median dose, 54 Gy) (11) . Based on this trial, we launched a multicenter Phase II study of SABR for HCC in 2012 in Korea (NCT01825824), which was conducted under the authorization and cooperation of the Korea Radiation Oncology Group (KROG 12-02). The purpose of this study was to evaluate the efficacy of high-dose SABR using 60 Gy in three fractions for HCC ≤5 cm in a multicenter setting.
Multicenter trials have the advantages of rapid recruitment of the necessary number of patients and clearer results that enhance external validity, as the patient samples of multicenter trials are supposed to be representative (12) . However, the successful conduct of multicenter trials requires strong efforts in regards to quality assurance (QA). Several retrospective analyses for the QA of RT impact on patient outcome in prospective trials have shown that non-adherence to protocol-specified RT requirements was associated with a detrimental effect on clinical outcome (13) . The institutions that participated in our KROG 12-02 study have various RT treatment machines and RT planning systems, and use various RT planning techniques. Therefore, we performed a planning dummy run procedure to evaluate dosimetric differences and to assess the incidence and range of possible protocol deviation for an index case.
Patients and methods

Study protocol
The study eligibility criteria were: (i) age ≥20 years; (ii) an initial diagnosis of primary HCC or recurrence; (iii) unresectable disease status; (iv) Child-Pugh (CP) score 5-7 disease; (v) an Eastern Cooperative Oncology Group performance status of 0 or 1; (vi) a greatest tumor diameter ≤5 cm; (vii) HCC with at least 3 cm apart from gastrointestinal tract; (viii) normal liver volume [NLV, the total liver volume minus the cumulative gross tumor volume (cGTV)] >700 ml; (ix) incomplete response after trans-arterial chemo-embolization (TACE) of 1-5 attempts; (x) single or multiple lesions including portal vein tumor thrombosis, which were included in the radiation field with one or consecutive sessions of SABR and (xi) no evidence of an uncontrolled lesion at any other site.
The cGTV was defined as an enhancing mass visualized on computed tomography (CT) and/or magnetic resonance imaging. The cGTV was considered equal to the internal target volume (ITV). The planning target volume (PTV) was defined as the ITV plus 4 mm in the longitudinal direction and the ITV plus 2 mm in all other directions. The prescription dose to the PTV was 60 Gy in three fractions; at least 90% of the prescription dose covered the PTV. Organs at risk (OARs) included the normal liver, spinal cord, esophagus, stomach and intestine; at least 700 cc or 70% of the NLV should not receive a total dose of >17 Gy; the maximum dose to the spinal cord should not exceed 22 Gy and 0.25 cc or less of irradiated volume of the spinal cord >18 Gy; the maximum dose to the esophagus, stomach and intestine should not exceed 30 Gy. Other OARs were restricted to the lowest levels possible, although these OARs were not documented.
This study was approved by the Korea Institute of Radiological and Medical Sciences Institutional Review Board (IRB No. K-1205-001-005). Written informed consent for participation in this study was obtained from the patients.
Dummy run procedure
The first dummy run case was a 72-year-old man with 3.4 cm HCC at the liver dome (Segment 8). He initially received one cycle of TACE for HCC at Segment 7 in 2007 and achieved a complete response. During the follow-up period, HCC recurred at Segment 8 in 2012, and he received an additional two cycles of TACE. The follow-up CT after TACE showed a viable tumor with incomplete lipiodol uptake at Segment 8. He was a hepatitis B virus carrier with liver cirrhosis. The baseline liver function was CP score of five. The GTV, PTV and NLV were 16, 32 and 1059 ml, respectively. The second dummy run case was a 71-year-old woman with 2.4 cm HCC at the liver dome (Segment 8). She received one cycle of TACE. The follow-up CT after TACE showed a viable tumor with incomplete lipiodol uptake at Segment 8 near the heart. She was a hepatitis B virus carrier. The baseline liver function was CP score of five. The GTV, PTV and NLV were 5 , 12 and 1236 ml, respectively.
For the dummy run, Digital Imaging and Communications in Medicine (DICOM) RT format files of the planning CT and the structure set including the PTV and OARs were provided to the participating institutions. Among the seven participating institutions, six were requested to participate in this dummy run procedure; one institution did not enroll actual patient. Institutions downloaded the DICOM files of two dummy cases from a website, and RT plans were generated according to the study protocol. Subsequently, the DICOM RT format files of radiation doses were uploaded to a website for review. In addition, completion of a facility questionnaire, including information on simulation and planning parameters, was required.
Dosimetric analysis
The DICOM files of each institution were imported into an MIM workstation (MIM Software Inc., Cleveland, OH). All planning dummy run procedures were reviewed by two independent reviewers at Soonchunhyang University College of Medicine, Bucheon. Dosimetric quality was evaluated by dose-volume histogram (DVH) analysis. To assess the GTV coverage, the maximum (D max , Gy), minimum (D min ) and mean (D mean ) dose to the GTV were acquired. To assess the PTV coverage, the V 90% (percentage of the PTV receiving 90% of the prescription dose) and D max were acquired. In addition, dose at 2% of the PTV (D 2% ), D 50% , D 95% , D 98% , D 99% , D min and D mean was also acquired. To assess high-dose spillage, the percent ratio of the cumulative volume of all tissue outside the PTV receiving a dose >105% of the prescription dose to the PTV (V 63Gy , %) was recorded. To assess intermediate-dose spillage, the percent ratio of the maximum dose at 2 cm from the PTV to the prescription dose (D 2cm , %) and the ratio of the 50% prescription isodose volume to the PTV (R 50% ) were recorded. The conformity of the plans was assessed according to the conformity index (CI), defined as the ratio of the prescription isodose volume to the PTV. The homogeneity index (HI) was defined as D 2% of the PTV minus D 98% of the PTV divided by the prescription dose. The mean dose of NL, NLV receiving <17 Gy (rV 17Gy, reverse V 17Gy ), NLV receiving >20 Gy (V 20Gy ) and NLV receiving >30 Gy (V 30Gy ) were derived from DVHs. For the second dummy run case, the maximum doses of the heart at 0.03 ml (D 0.03ml ) and at 15 ml (D 15ml ) were derived from DVHs. We considered deviation ≤5% of the PTV_V 90% according to the study protocol as none deviation, deviation from 5% to 10% as minor deviation and deviation >10% as major deviation. In terms of OAR protection, we considered satisfaction of OAR constraints in the study protocol as none deviation, deviation ≤5% as minor deviation and deviation >5% as major deviation. If no prescription dose constraints for the PTV and OARs were mentioned in the study protocol, we applied the NRG Oncology BR001 protocol and NRG Oncology the Radiation therapy Oncology Group (RTOG) 0915 protocol as the reference points (14, 15) . The detailed dose constraints of these study protocols are available in Supplementary material 1.
Results
Simulation and planning parameters at the participating institutions are shown in Table 1 . For the liver motion control, institutions used various methods; forced shallow breathing with abdominal compression was the most commonly applied method. During the study, four-dimensional (4D) CT was applied in three institutions. The remaining three institutions acquired CT images from at least two different phases. Most institutions used a single treatment machine; Institution B had two treatment machines and physician could select the suitable treatment machine on a case-by-case basis. Fig. 1 and Fig. 2 show isodose distributions for both dummy run cases. Fig. 3 shows DVHs of the PTV and NLV for both dummy run cases. Detailed contents for dosimetric parameters are summarized in Tables 2 and 3 . For the dummy run procedure, three beam delivery modes were applied: static intensity-modulated RT in two institutions, CyberKnife in two institutions and RapidArc in two institutions. In terms of the PTV coverage, the V 90% of all participants complied with the study protocol. The D max of the PTV ranged from 102% to 127% of the prescription dose and was located within the PTV for all plans. For the second dummy run case, however, the values of the PTV_D 99% were variable; the D 99% of institutions A and C received <90% of the prescription dose, which was lower than that in NRG Oncology RTOG 0915 protocol. This was because the heart was located near the PTV; Institutions A and C showed the lowest value of the heart_D 0.03ml . Although a dose >105% of the prescription dose occurred outside the PTV, the V 63Gy of all plans was <15%. To assess intermediate-dose spillage based on NRG Oncology RTOG 0915 protocol, the D 2cm of Institutions C and E showed major deviation for the first case; the D 2cm of Institutions A and E showed major deviation and Institution C showed minor deviation for the second case. In terms of the R 50% , Institution C showed major deviation and Institutions E and F showed minor deviation for the first case. There was no major deviation for the second case. However, the R 50% of five institutions except Institution D showed minor deviation. The values of the CI of all plans were ≤1.2 within minor deviation. The NL_rV 17Gy of all plans were >700 ml; the NL_ mean was the lowest in institutions using RapidArc. The NRG-BR001 protocol recommended a D 0.03ml ≤30 Gy and D 15ml ≤24 Gy for the heart. Although the heart_D 0.03ml of all institutions were >30 Gy in this dummy run, the D 15ml were <15 Gy. This reflected rapid dose fall-off near the heart, and an extremely small volume received a relatively high dose. Other OAR constraints including the esophagus, stomach and intestine fully complied with the study protocol.
Discussion
This dummy run procedure showed acceptable compliance with the study protocol. All plans showed proper PTV coverage based on a V 90% . However, we found the possibility of underdose to the PTV margin if the HCC lesion was located near OARs. For the second dummy run case near the heart, deviation of the values of the PTV_D 99% occurred in two institutions. Few studies have documented dose limitation to the PTV located with respect to OARs.
Sequential Phase I and II trials of SABR for HCC using 30-54 Gy in six fractions allowed a minimum dose of 30 Gy to the PTV margin if required to respect surrounding tissues tolerance (7). They showed a dose-response relationship with respect to local control on univariate analysis, however, lost statistical significance on multivariate analysis. In a recent study at the University of Michigan, RT doses of 27-60 Gy in three or five fractions were prescribed to the isodose surface covering 99.5% of the PTV, accepting regional underdose when necessary to satisfy normal tissue limits (16) . There was no dose-response; they suggested that the use of sufficiently ablative RT doses might explain why there was no dose-response relationship with respect to local control. However, a Japanese Radiological Society multi-institutional SBRT study group suggested that relatively lower treatment outcome compared with that reported in another Japanese study might be caused by the difference in prescription point to the PTV; prescription to the PTV surface than D 95% of the PTV or isodose center might increase the local control rate when a similar RT dose was administered (17, 18) . Because underdose to the PTV margin with intra-fractional movement could induce marginal recurrence, the association between the PTV margin dose and local control rate should be evaluated. We expect that planned individual case review as the next QA step might give some clues. sIMRT, static intensity-modulated radiotherapy; GTV, gross tumor volume; D max , maximal point dose; D min , minimum point dose; PTV, planning target volume; V 90%, percentage of the PVT receiving 90% of the prescription dose; V 63Gy , the percent ratio of the cumulative volume of all tissue outside the PTV receiving a dose >105% of the prescription dose to the PTV; D 2cm , the percent ratio of the maximum dose at 2 cm from the PTV to the prescription dose; R 50% , the ratio of the 50% prescription isodose volume to the PTV volume; HI, homogeneity index, defined as D 2% of the PTV minus D 98% of the PTV divided by the prescription dose; CI, conformity index, defined as the prescription isodose volume to the PTV volume; NL, normal liver; NL_rV 17Gy, NLV receiving <X Gy, reverse V 17Gy ; NL_V XGy , NLV receiving >X Gy.
Although the study protocol did not restrict high-dose spillage and intermediate-dose spillage, the values of high-dose spillage of all plans (V 63Gy ) complied with NRG Oncology RTOG 0915 protocol. However, there was a considerable variation in intermediate-dose spillage. Rapid dose fall-off outside the PTV is a distinct feature of SABR to deliver a high dose to the tumor without OAR damage. One article defined this area as the Red Shell concept, especially the Outer Red Shell (19) . The tissues in the Outer Red Shell receive a dose that is between the prescription dose and the tissue safe constraint dose. The RTOG protocol suggested the reference values of the thickness of the Outer Red Shell as D 2cm and R 50% according to size of the PTV. However, we pay attention to interpretation. First, the RTOG reference value did not represent the absolute value, although details about dosimetric parameters are well documented. For example, Holt A et al. (20) applied slightly loosen D 2cm , considering the use of a different dose-calculation algorithm. Second, rapid dose fall-off to minimize the thickness of the Outer Red Shell induced dose heterogeneity of the PTV and resulted in additional costs by using numerous radiation beams (or arcs), especially the non-coplanar beams distributed in a wide solid angle, crossing within the target (21) . However, this is not essential as in the first dummy case, when the PTV is located apart from OARs and the NLV is sufficient. Finally, when a critical OAR is close to the PTV, reducing the dose to the OAR could result in a larger volume of the Outer Red Shell, particularly for the surrounding tissue on the side opposite the critical OAR. Minor deviation of the R 50% occurred at five institutions for the second dummy case, which was also caused by reducing the dose to the heart. Further studies would be needed in order to determine an association between an increase in intermediate-dose spillage and OAR toxicity.
In conclusions, this planning dummy run procedure for a multicenter Phase II study of SABR for HCC in Korea showed acceptable compliance, although the participating institutions used variable treatment machines and planning techniques. However, we found the possibility of underdose to the PTV when the HCC lesion was located near OARs such as the heart. There was considerable variation in intermediate-dose spillage according to the HCC location. Based on this dummy run, we will conduct individual case reviews to minimize the effect of study protocol deviation and strengthen the reliability of the treatment outcome.
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